Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 304

Results For "clinic"

3611 News Found

CanSinoBIO's Convidecia approved as heterologous booster in China
News | February 21, 2022

CanSinoBIO's Convidecia approved as heterologous booster in China

Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants


Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Biotech | February 21, 2022

Enhertu Phase III results to redefine how metastatic breast cancer is classifed

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.


Panacea Biotech partners with GOI to develop protective vaccine against betacoronavirus
News | February 21, 2022

Panacea Biotech partners with GOI to develop protective vaccine against betacoronavirus

CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan


Valneva receives funding for Covid-19 vaccine from Scotland
Biotech | February 21, 2022

Valneva receives funding for Covid-19 vaccine from Scotland

The grants are expected to be received over the next three years, commencing March 2022


Corbevax receives EUA for 12-18 age group
News | February 21, 2022

Corbevax receives EUA for 12-18 age group

It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19


Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
Drug Approval | February 20, 2022

Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy

Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear


GSK pauses phase III RSV maternal vaccine candidate programme
News | February 20, 2022

GSK pauses phase III RSV maternal vaccine candidate programme

This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


Indian pharma industry needs a winning partnership
News | February 19, 2022

Indian pharma industry needs a winning partnership

The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines


Covid-19 fuels innovative PCR-based detection methods
Medical Device | February 19, 2022

Covid-19 fuels innovative PCR-based detection methods

According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years